GlassScriptPhysician profile
Chisom Onuoha
NPI 1447519376
$895.78
in general payments reported to CMS, 2019-2025
19 companies · $65.47 in 2025
The $65.47 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $39.38 · 2021: $146 · 2022: $68.24 · 2023: $157 · 2024: $204 · 2025: $65.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $175.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $129.98 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $87.20 | 2019-2025 | Opdivo |
| Pfizer INC. | $72.28 | 2021-2024 | |
| Janssen Biotech, INC. | $57.79 | 2021-2023 | Darzalex, Tecvayli |
| Taiho Oncology, INC. | $51.73 | 2019-2024 | |
| Gilead Sciences, INC. | $51.18 | 2023-2024 | Trodelvy |
| Lilly USA, LLC | $38.67 | 2024 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $30.81 | 2024-2025 | |
| Genzyme Corporation | $30.28 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.69 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $29.07 | 2023 | |
| Veran Medical Technologies, INC. | $22.38 | 2019 | |
| Glaxosmithkline, LLC. | $17.61 | 2021 | |
| Merck Sharp & Dohme LLC | $16.37 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $14.94 | 2023 | Rezlidhia, Tavalisse |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.89 | 2024 | Lifevest |
| Seagen INC. | $13.89 | 2023 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chisom Onuoha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.